REDWOOD CITY, Calif. — October 29, 2025 — Leads & Copy — Revolution Medicines, Inc. (Nasdaq: RVMD) will report its third-quarter 2025 financial results on Wednesday, November 5, 2025, after the market closes. Revolution Medicines’ senior management team will host a live webcast at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results and provide a corporate progress update.
To access the live webcast, or the archived webcast afterward, visit: https://ir.revmed.com/events-and-presentations. A replay will be available on the company’s website for at least 14 days following the live webcast.
Revolution Medicines is a late-stage clinical oncology company that develops novel targeted therapies for patients who have RAS-addicted cancers. Its R&D pipeline includes RAS(ON) inhibitors that are designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON) inhibitors in clinical development include daraxonrasib (RMC-6236), a RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), a RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor. The company anticipates that RMC-5127, a RAS(ON) G12V-selective inhibitor, will be its next RAS(ON) inhibitor to enter clinical development. Additional development opportunities in the company’s pipeline focus on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
Revolution Medicines Media & Investor Contact:
media@revmed.com
investors@revmed.com
Source: Revolution Medicines, Inc.
